Skip to main content

UroLift — Prostatic Urethral Lift

UroLift mechanically retracts obstructing prostate tissue with permanent implants, without resecting or thermally ablating it. Each implant has a nitinol capsular tab, a stainless-steel urethral end-piece, and a connecting PET monofilament suture. The capsular and urethral metals are not interchangeable descriptions.[1]

For selection and technique, see Prostatic Urethral Lift.

Device and Labeled Selection​

The checked US UroLift 2 instructions indicate treatment in men 45 years or older, including lateral- and median-lobe hyperplasia, and contraindicate use when prostate volume exceeds 100 cc. An obstructing median lobe is therefore not a blanket label contraindication. Trial populations and professional-guideline recommendations may be narrower.[1]

Other listed contraindications include UTI, urethral conditions preventing delivery-system insertion, incontinence due to an incompetent sphincter, and current gross hematuria. Review material allergy and the patient's specific anatomy and prior procedures against the full instructions.[1]

The UroLift 2 handle is for one patient and is validated for up to eight implant-cartridge deployments; each cartridge is single use. Implant number depends on anatomy and the required opening. The instructions describe an average of four to six implants and a maximum of ten per patient, which may require another handle.[1]

Evidence and Reconstructive Relevance​

The L.I.F.T. study randomized 206 participants and demonstrated symptom improvement versus sham at three months, with longer-term follow-up of treated patients. MedLift evaluated median-lobe treatment in a separate 45-participant cohort; it was not the median-lobe arm of that randomized trial. Favorable sexual-function results do not guarantee absence of all sexual symptoms or retreatment.[1]

Misplaced, exposed or loose components can require removal and may lead to encrustation, stones, bleeding or persistent symptoms. Future endoscopic procedures should account for the implants. The implanted components are MR Conditional, with model-specific field, gradient and RF limits; MRI artifact can affect the prostate assessment. The delivery system itself should not be taken into an MRI environment.[1]

References​

1. Teleflex/NeoTract. UroLift 2 System Instructions for Use, US. L00127-01 Rev E, June 2022; linked from current manufacturer IFU page, accessed September 12, 2026. Instructions for use.